Testicular cancer historical perspective
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Gertrude Djouka, M.D.[2]
Overview
Overview
There is a limited information about the historical perspective of testicular germ cell tumors. Leydig cells were first discovered by Franz Leydig who was a German anatomist in 1870.
Historical Perspective
Historical Perspective
Discovery
- There is a limited information about the historical perspective of testicular tumors. Leydig cells were first discovered by Franz Leydig who was a German anatomist in 1870.[1]
Landmark Events in the Development of Treatment Strategies
- In 1965, Dr. Barnett Rosenberg, a biophysics research at Michigan State University, discovered cisplatin drug which affects the cells division. The blockage of cell division was from the platinum found in the electrodes. The experiment was tested in the mice at low dose of cisplatin since cisplatin at high doses might cause renal toxicities.[2][3]
- In 1972, National Cancer Institute stepped in and participated in the funding of the clinical trials in human patients with advanced testicular cancers under the supervision of Dr. lawrence Einhorn at Indiana University.
- In 1978, Food and Drugs Administration (FDA) approved cisplatin drug for the treatment of testicular cancer based on successful clinical trials. Cisplatin has improved the lives of many patients diagnosed with testicular cancers and others when combining with others drugs.[4]
References
References
- ↑ Al-Agha OM, Axiotis CA (February 2007). “An in-depth look at Leydig cell tumor of the testis”. Arch. Pathol. Lab. Med. 131 (2): 311–7. doi:10.1043/1543-2165(2007)131[311:AILALC]2.0.CO;2. PMID 17284120.
- ↑ “Discovery – Cisplatin and The Treatment of Testicular and Other Cancers – National Cancer Institute, The “Accidental” Cure—Platinum-based Treatment for Cancer: The Discovery of Cisplatin”.
- ↑ Nakamura T, Miki T (February 2010). “Recent strategy for the management of advanced testicular cancer”. Int. J. Urol. 17 (2): 148–57. doi:10.1111/j.1442-2042.2009.02431.x. PMID 20377835.
- ↑ Gómez-Ruiz S, Maksimović-Ivanić D, Mijatović S, Kaluđerović GN (2012). “On the discovery, biological effects, and use of Cisplatin and metallocenes in anticancer chemotherapy”. Bioinorg Chem Appl. 2012: 140284. doi:10.1155/2012/140284. PMC 3401524. PMID 22844263.
Looking for the patient version?
© 2026 MyEClinic – IFTM Institut für Telematik in der Medizin GmbH